Raymond James Financial Services Advisors Inc. Acquires Shares of 8,473 Biohaven Ltd. (NYSE:BHVN)

Raymond James Financial Services Advisors Inc. bought a new stake in Biohaven Ltd. (NYSE:BHVN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 8,473 shares of the company’s stock, valued at approximately $363,000.

Several other large investors have also modified their holdings of the stock. US Bancorp DE lifted its position in Biohaven by 19.1% in the first quarter. US Bancorp DE now owns 586 shares of the company’s stock valued at $70,000 after purchasing an additional 94 shares during the period. Advisor Group Holdings Inc. boosted its stake in shares of Biohaven by 219.8% in the fourth quarter. Advisor Group Holdings Inc. now owns 8,606 shares of the company’s stock valued at $120,000 after buying an additional 5,915 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new position in Biohaven during the first quarter worth $143,000. Creative Planning acquired a new position in Biohaven during the fourth quarter worth $147,000. Finally, Tower Research Capital LLC TRC raised its position in Biohaven by 72.6% in the second quarter. Tower Research Capital LLC TRC now owns 6,677 shares of the company’s stock worth $160,000 after acquiring an additional 2,809 shares in the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Wall Street Analysts Forecast Growth

BHVN has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Biohaven in a research note on Thursday. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price target on shares of Biohaven in a research report on Tuesday, April 9th. TD Cowen upped their price target on Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. HC Wainwright lifted their price objective on Biohaven from $50.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, UBS Group started coverage on Biohaven in a report on Tuesday, February 6th. They issued a “buy” rating and a $59.00 target price on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $52.00.

Biohaven Stock Down 7.5 %

NYSE BHVN opened at $38.99 on Monday. Biohaven Ltd. has a fifty-two week low of $12.35 and a fifty-two week high of $62.21. The business has a fifty day moving average of $51.84 and a 200-day moving average of $41.60. The stock has a market cap of $3.19 billion, a price-to-earnings ratio of -6.89 and a beta of 1.18.

Biohaven (NYSE:BHVN) last released its earnings results on Thursday, February 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). As a group, analysts anticipate that Biohaven Ltd. will post -5.85 EPS for the current year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.